Y Intercept Hong Kong Ltd Has $2.04 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

Y Intercept Hong Kong Ltd grew its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 899.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,635 shares of the company’s stock after purchasing an additional 29,369 shares during the period. Y Intercept Hong Kong Ltd owned about 0.07% of Prestige Consumer Healthcare worth $2,036,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Assenagon Asset Management S.A. bought a new position in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $1,890,000. AXQ Capital LP purchased a new position in Prestige Consumer Healthcare in the second quarter worth about $694,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after buying an additional 70,376 shares during the last quarter. Tributary Capital Management LLC increased its holdings in Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after buying an additional 231,969 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Prestige Consumer Healthcare by 13.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,571 shares of the company’s stock worth $765,000 after purchasing an additional 1,134 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $63.18 on Thursday. The stock has a market cap of $3.04 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 2.01 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a 52-week low of $57.25 and a 52-week high of $90.04. The business has a 50-day simple moving average of $62.32 and a 200-day simple moving average of $64.48. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The company had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same quarter in the prior year, the business posted $1.09 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analyst Weigh In

PBH has been the subject of a number of analyst reports. Oppenheimer cut their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Jefferies Financial Group decreased their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average price target of $85.33.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).